Drug Trial Radar · NCT04444895
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
Last checked: Nov 20, 2026Latest source record: Jun 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Feb 5, 2021
Primary completion
May 5, 2023
Study completion May 5, 2023
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Takeda Development Center Americas, Inc.
- First posted
- Jun 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term safety and efficacy of repeated subcutaneous (SC) administration of lanadelumab in adolescents and adults with non-histaminergic angioedema with normal C1-inhibitor who completed study SHP643-303 (NCT04206605).
Conditions
- Angioedema
Interventions
LanadelumabDrug
Lanadelumab SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Treatment PeriodTime frame: From Day 0 up to Day 182
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Follow-upTime frame: From Day 183 up to Day 196
Locations
35 sites in 10 countries. Site status is shown where the registry gives one.
Clinical Research Center of Alabama
Birmingham, Alabama
Medical Research of Arizona
Scottsdale, Arizona
UCSD Angioedema Center
San Diego, California
Allergy and Asthma Clinical Research Inc
Walnut Creek, California
Asthma and Allergy Associates, PC
Colorado Springs, Colorado
Rush University Medical Center
Chicago, Illinois
Kanarek Allergy, Asthma and Immunology
Overland Park, Kansas
Institute for Asthma & Allergy, P.C.
Chevy Chase, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
Washington University
St Louis, Missouri
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio
Optimed Research, LTD
Columbus, Ohio
Seattle Allergy & Asthma Research Institute
Seattle, Washington
Ottawa Allergy Research Corporation
Ottawa, Ontario, Canada
Clinique Specialisee en Allergie de la Capitale
Québec, Quebec, Canada
Hôpital Saint-Antoine
Paris, France
Klinikum rechts der Isar der TU
Munich, Bavaria, Germany
Klinikum der Johann Wolfgang Goethe-Universitaet pt
Frankfurt am Main, Hesse, Germany
Semmelweis Egyetem
Budapest, Hungary
Azienda Socio Sanitaria Territoriale Fatebenefratelli (Presidio Ospedale Sacco)
Milan, Italy
Azienda Ospedaliera Universitaria "Federico II"
Naples, Italy
Azienda Ospedaliera Universitaria OO. RR. S. Giovanni di Dio e Ruggi D'Aragona
Salerno, Italy
A.O. Ospedali riuniti Villa Sofia - Cervello,
Palermo, Palermo Palermo, Italy
Hiroshima University Hospital
Hiroshima, Hiroshima, Japan
Kobe University Hospital
Kobe, Hyōgo, Japan
Clover Hospital
Fujisawa-shi, Kanagawa, Japan
Amsterdam UMC
Amsterdam, Netherlands
Universitair Medisch Centrum Groningen
Groningen, Netherlands
UMC Utrecht
Utrecht, Netherlands
NZOZ Homeo Medicus, Poradnia Alergologiczna
Bialystok, Poland
"ALL-MED" Specjalistyczna Opieka Medyczna Filia
Wroclaw, Poland
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario Cruces
Barakaldo, Vizcaya, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.